Therapeutic effect of anti-TNF mAb, CTLA-4Ig, and anti-IL-6 mAb in GPI-induced arthritis

Glucose-6-phosphate isomerase (GPI)-immunized mice were treated with anti-tumor necrosis factor (TNF)-α mAb; anti-IFN-γ mAb or anti-IL-12 mAb; cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA-4Ig; on days 8 and 12); CTLA-4Ig (on days 12 and 16); and or anti-IL-6 mAb just after the onset of arthritis (on day 8, on days 8 and 12, or days 12 and 16; arrow). The mean clinical index (± standard error) was examined throughout the study. *< 0.05, **< 0.01, by Mann-Whitney's U test. n = 6 mice in each group. Hematoxylin and eosin staining at day 21 (×40) is also shown: anti-TNF-α mAb, control antibody, and CTLA-4Ig (on days 8 and 12).<p><b>Copyright information:</b></p><p>Taken from "Therapeutic effects of antibodies to tumor necrosis factor-α, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis"</p><p>http://arthritis-research.com/content/10/3/R66</p><p>Arthritis Research & Therapy 2008;10(3):R66-R66.</p><p>Published online 5 Jun 2008</p><p>PMCID:PMC2483457.</p><p></p

Concentration of inflammatory cytokines in serum of mice with GPI-induced arthritis

After immunization with glucose-6-phosphate isomerase (GPI), serum samples were collected from GPI-induced DBA/1 mice at the indicated time points (days 0, 7, 14, and 28). Serum concentrations of tumor necrosis factor (TNF)-α (solid circle), IL-6 (open square), IL-1β (open triangle), or IFN-γ (open diamond) were determined by enzyme-linked immunosorbent assay. Data are expressed as mean ± standard error. = 3 mice in each group. *< 0.05, by Mann-Whitney's U-test.<p><b>Copyright information:</b></p><p>Taken from "Therapeutic effects of antibodies to tumor necrosis factor-α, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis"</p><p>http://arthritis-research.com/content/10/3/R66</p><p>Arthritis Research & Therapy 2008;10(3):R66-R66.</p><p>Published online 5 Jun 2008</p><p>PMCID:PMC2483457.</p><p></p

Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) – A prospective, multicenter, single arm pilot clinical trial

<p><b>Objectives:</b> To preliminarily evaluate the feasibility of maintenance therapy with reduced dose of intravenous abatacept (ABT) to 250 mg/body/month after achieving remission or low disease activity (LDA).</p> <p><b>Patients and methods:</b> RA patients treated with ABT at 13 sites were enrolled in this prospective interventional pilot study during the period between March 2013 and March 2015. Inclusion criteria were (1) age at 20 years or older, (2) under treatment with monthly intravenous ABT at approved doses, (3) DAS28-CRP lower than 2.7 at least for 6 months, (4) agreed to join this trial with written informed consent and (5) body weight under 125 kg. Enrolled patients were maintained with intravenous monthly ABT at a reduced dose of 250 mg/body (MATADOR protocol). The primary end point was the proportion of the patients continued with MATADOR protocol at week 48. MATADOR protocol was discontinued upon disease flare or other reasons such as patients’ request or severe adverse event (AE). Disease activities and structural changes were also evaluated.</p> <p><b>Results:</b> Fifty-three patients fulfilled the entry criteria and were followed for 1-year. MATADOR protocol was continued for 1-year in 43 (81%) of the evaluated patients. Three patients experienced severe AEs. Mean DAS28-CRP and remission rate were 1.56 and 88% when ABT reduced and 1.80 and 81% at 1-year, respectively. Structural remission was achieved in 34 out of 42 evaluated patients.</p> <p><b>Conclusions:</b> Reduced dose of intravenous ABT was proposed as a feasible choice for maintenance therapy for RA after achievement of remission/LDA, although further randomized trials would be awaited.</p